Physiologically based modelling of tranexamic acid pharmacokinetics following intravenous, intramuscular, sub-cutaneous and oral administration in healthy volunteers. (2021)
Attributed to:
The CRASH-3 Trial: Tranexamic acid for the treatment of significant traumatic brain injury.
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.ejps.2021.105893
PubMed Identifier: 34087356
Publication URI: http://europepmc.org/abstract/MED/34087356
Type: Journal Article/Review
Volume: 164
Parent Publication: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
ISSN: 0928-0987